| Not Yet Recruiting | Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk B NCT06732388 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial NCT07206589 | Mayo Clinic | N/A |
| Recruiting | A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophag NCT07392892 | Pfizer | Phase 2 / Phase 3 |
| Not Yet Recruiting | ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu NCT06824363 | University of California, Irvine | EARLY_Phase 1 |
| Not Yet Recruiting | Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma NCT07059611 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Recruiting | Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients W NCT07282912 | Yale University | Phase 2 |
| Recruiting | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer NCT07432295 | I-Mab Biopharma US Limited | Phase 2 |
| Recruiting | A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for R NCT07059299 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 1 |
| Recruiting | First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors NCT07284186 | Plexium, Inc. | Phase 1 |
| Enrolling By Invitation | Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Eso NCT07212491 | Mayo Clinic | — |
| Recruiting | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy NCT07223424 | Diwakar Davar | Phase 2 |
| Not Yet Recruiting | Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma NCT07222657 | Case Comprehensive Cancer Center | Phase 2 |
| Recruiting | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors NCT07182149 | Normunity AccelCo, Inc. | Phase 1 |
| Not Yet Recruiting | Low-Dose Radiotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma Resistant to First-Line Che NCT07164690 | Fudan University | Phase 2 |
| Recruiting | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors NCT07090499 | Pfizer | Phase 1 |
| Recruiting | A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk NCT06523374 | University Hospital, Antwerp | N/A |
| Recruiting | Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors NCT07021066 | SystImmune Inc. | Phase 1 |
| Recruiting | Combination of Chemotherapy and Adaptive MR-Guided Radiotherapy to Improve Outcomes in Patients With Esophagea NCT07359443 | UMC Utrecht | Phase 1 |
| Recruiting | Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms NCT06687603 | Case Comprehensive Cancer Center | N/A |
| Recruiting | Outcomes of a Single Chest Drain vs Two Drains NCT07125248 | Khyber Teaching Hospital | N/A |
| Recruiting | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination NCT06628310 | AbbVie | Phase 2 |
| Recruiting | Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype NCT06532734 | Denver Health and Hospital Authority | — |
| Terminated | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMAR NCT06560645 | Prelude Therapeutics | Phase 1 |
| Recruiting | A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Es NCT05563766 | VA Office of Research and Development | Phase 2 |
| Recruiting | A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer NCT06623396 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors NCT06549816 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatm NCT06324357 | Boehringer Ingelheim | Phase 1 / Phase 2 |
| Recruiting | Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma NCT06340711 | Weill Medical College of Cornell University | Phase 2 |
| Recruiting | A Study of KK2269 in Adult Participants With Solid Tumors NCT06266299 | Kyowa Kirin Co., Ltd. | Phase 1 |
| Recruiting | Obeticholic Acid for Prevention in Barrett's Esophagus NCT04939051 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Trans-Oral Sampling as an Alternative Surveillance of Barrett's Esophagus Pilot NCT07490340 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | — |
| Recruiting | Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples NCT06071845 | Mayo Clinic | N/A |
| Recruiting | Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas NCT05745857 | University Medical Center Groningen | Phase 2 |
| Not Yet Recruiting | Chemotherapy in the Context of Esophageal and Gastroesophageal Junction Cancer Cachexia NCT05954117 | University Hospital, Clermont-Ferrand | N/A |
| Active Not Recruiting | Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Tr NCT05480384 | Brown University | Phase 2 |
| Active Not Recruiting | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors NCT05945823 | Taiho Oncology, Inc. | Phase 2 |
| Recruiting | Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors NCT06005493 | AstraZeneca | Phase 1 / Phase 2 |
| Completed | A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma NCT06381583 | City of Hope Medical Center | — |
| Unknown | Lucid Registry Study NCT05965999 | Lucid Diagnostics, Inc. | — |
| Unknown | Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow NCT05591053 | Activ Surgical | N/A |
| Unknown | Public's Intended Uptake and Views on Organization of Esophageal Cancer Screening NCT05690958 | Radboud University Medical Center | — |
| Recruiting | Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia NCT05753748 | University of Colorado, Denver | N/A |
| Recruiting | A Multicenter Prospective Cohort Study Comparing Random Biopsies Versus Wide-Area Transepithelial Brush-Sampli NCT05642338 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | — |
| Recruiting | Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergo NCT05530343 | University of Colorado, Denver | N/A |
| Unknown | Early Detection of Cancer Onset Based on Sensing Field Cancerization at the Organ Level in the Alimentary Trac NCT05247346 | University Medical Center Groningen | N/A |
| Completed | Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy NCT05394740 | National Cancer Center Hospital East | Phase 1 / Phase 2 |
| Completed | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients NCT05411133 | Arbele Pty Ltd | Phase 1 |
| Terminated | (VELA) Study of BLU-222 in Advanced Solid Tumors NCT05252416 | Blueprint Medicines Corporation | Phase 1 |
| Recruiting | TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer NCT05188313 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 3 |
| Active Not Recruiting | Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of NCT04929392 | City of Hope Medical Center | Phase 2 |
| Terminated | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresect NCT04683939 | BioNTech SE | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-posit NCT05152147 | Jazz Pharmaceuticals | Phase 3 |
| Completed | Endoscopic Radiofrequency Ablation Versus Hybrid Argon Plasma Coagulation in the Treatment of Barrett's Esopha NCT05051475 | Centre of Postgraduate Medical Education | N/A |
| Recruiting | Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) NCT05177133 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 2 |
| Recruiting | Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma NCT03961945 | Mayo Clinic | N/A |
| Recruiting | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors NCT04900818 | I-Mab Biopharma US Limited | Phase 1 |
| Active Not Recruiting | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Express NCT04802876 | SOLTI Breast Cancer Research Group | Phase 2 |
| Recruiting | Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma NCT04682158 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HE NCT04499924 | Seagen Inc. | Phase 2 / Phase 3 |
| Completed | The Microbiome, Bile Acids, and Notch in Barrett's Esophagus (BE) NCT05524844 | Columbia University | — |
| Active Not Recruiting | Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy NCT04554771 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 2 |
| Recruiting | RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial). NCT04306458 | University Medical Center Mainz | N/A |
| Completed | Impact of Arterial Partial Pressure of Oxygen on Anastomotic Leakage After Esophagectomy NCT07309991 | Sun Yat-sen University | — |
| Terminated | Nitrates and IL-8 in Barrett's Esophagus NCT04642690 | Mayo Clinic | — |
| Active Not Recruiting | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER NCT04430738 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Recruiting | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies NCT04114136 | Dan Zandberg | Phase 2 |
| Withdrawn | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in P NCT03982173 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Recruiting | Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and G NCT04150640 | University of Wisconsin, Madison | Phase 2 |
| Unknown | Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE NCT04295811 | Lucid Diagnostics, Inc. | N/A |
| Recruiting | A Study of Sigvotatug Vedotin in Advanced Solid Tumors NCT04389632 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Completed | Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE NCT04293458 | Lucid Diagnostics, Inc. | N/A |
| Recruiting | Registry Platform Gastric/Esophageal Cancer (SAPHIR) NCT04290806 | iOMEDICO AG | — |
| Terminated | Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma NCT04089904 | University of Chicago | Phase 2 |
| Unknown | RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus NCT04159974 | University of Cologne | Phase 2 |
| Terminated | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumo NCT04060342 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Phase 1 |
| Suspended | Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Und NCT03604991 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Unknown | Maintaining Fitness During Neo-adjuvant Chemotherapy for Oesophago-gastric Cancer: a Feasibility Study NCT04194463 | Newcastle-upon-Tyne Hospitals NHS Trust | N/A |
| Terminated | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Canc NCT03809624 | Inhibrx Biosciences, Inc | Phase 1 |
| Completed | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas NCT03783936 | Ashwin Somasundaram | Phase 2 |
| Completed | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib NCT03339843 | Jules Bordet Institute | Phase 2 |
| Recruiting | Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other G NCT03539822 | Anwaar Saeed | Phase 1 / Phase 2 |
| Terminated | Rapid Assessment of Esophageal Adenocarcinoma Risk Test NCT03366012 | Columbia University | N/A |
| Withdrawn | Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroes NCT03592407 | City of Hope Medical Center | Phase 2 |
| Completed | OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma NCT03429816 | University Hospital Heidelberg | N/A |
| Unknown | Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer NCT03474341 | UMC Utrecht | — |
| Unknown | mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA) NCT03288350 | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 2 |
| Completed | The Microenvironment in Barrett's Esophagus NCT03060642 | Columbia University | — |
| Completed | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies NCT03365791 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment R NCT03223662 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analys NCT03015389 | CDx Diagnostics | — |
| Terminated | Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers NCT03122548 | Aduro Biotech, Inc. | Phase 2 |
| Active Not Recruiting | Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma NCT02998268 | Weill Medical College of Cornell University | Phase 2 |
| Active Not Recruiting | Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery NCT02962063 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Can NCT02872116 | Bristol-Myers Squibb | Phase 3 |
| Completed | Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patie NCT02890979 | OHSU Knight Cancer Institute | N/A |
| Completed | Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer NCT02606396 | Hunter Holmes Mcguire Veteran Affairs Medical Center | N/A |
| Active Not Recruiting | Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Ra NCT02521285 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies NCT02638909 | Criterium, Inc. | Phase 2 |
| Completed | Pilot Sudy: Resectable Esophageal Adenocarcinoma and the Relevance of CTC NCT02610764 | University Hospital Freiburg | N/A |
| Completed | Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome NCT02513784 | Columbia University | N/A |
| Unknown | Evaluation of MicroRNA Expression in Blood and Cytology for Detecting Barrett's Esophagus and Associated Neopl NCT02464930 | Midwest Biomedical Research Foundation | — |
| Suspended | Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advan NCT02366819 | University of Chicago | Phase 4 |
| Completed | Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer NCT02128243 | AIO-Studien-gGmbH | Phase 2 |
| Completed | Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management NCT02075905 | University of North Carolina, Chapel Hill | — |
| Completed | Esophageal Cytology With FISH in Detecting Esophageal Cancer NCT02100189 | OHSU Knight Cancer Institute | N/A |
| Completed | Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Materia NCT01970306 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcin NCT01932580 | McGill University | Phase 2 |
| Completed | DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma NCT03526328 | University of Oklahoma | — |
| Terminated | Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer NCT01307956 | University of Nebraska | Phase 2 |
| Completed | Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophagea NCT01196390 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Esophageal Protocol for Detection of Neoplasia in the Digestive Tract NCT01391208 | University of Michigan | Phase 1 |
| Unknown | Barrett's Esophagus Patient Registry NCT01776346 | Massachusetts General Hospital | — |
| Unknown | Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma NCT00964080 | Mebiopharm Co., Ltd | Phase 1 / Phase 2 |
| Terminated | Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adeno NCT00667420 | Massachusetts General Hospital | Phase 1 / Phase 2 |
| Completed | Micro-RNA (miR) Expression in Upper Gastrointestinal Mucosal Tissue NCT00909350 | Mayo Clinic | — |
| Completed | Confocal Endomicroscopy for Barrett's Esophagus NCT00487695 | Johns Hopkins University | Phase 3 |
| Terminated | Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adeno NCT00430027 | University of Colorado, Denver | N/A |
| Recruiting | Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registr NCT00574327 | Midwest Biomedical Research Foundation | — |